Allele-specific amplification

US9506111B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9506111-B2
Application numberUS-201314052416-A
CountryUS
Kind codeB2
Filing dateOct 11, 2013
Priority dateOct 20, 2008
Publication dateNov 29, 2016
Grant dateNov 29, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having a 3′-terminal nucleotide complementary to only one variant of the target sequence and having at least one nucleotide with a base covalently modified at the exocyclic amino group, wherein the allele-specific oligonucleotide is extended by a nucleotide-incorporating biocatalyst predominantly when hybridized to the variant of the target sequence for which it has said complementary 3′-terminal nucleotide.

First claim

Opening claim text (preview).

The invention claimed is: 1. A kit for allele-specific amplification of a target sequence, which exists in the form of several variant sequences, comprising (a) a first oligonucleotide, at least partially complementary to one or more variant of the target sequence; and (b) a second oligonucleotide, at least partially complementary to one or more variant of the target sequence and having a 3′-terminal nucleotide complementary to only one variant of the target sequence; wherein said second oligonucleotide is selected from a group consisting of SEQ ID NOs: 4, 5, 7, 8, 10, 11, and 18. 2. An oligonucleotide for performing an allele-specific amplification of a target sequence, which exists in the form of several variant sequences, comprising a sequence at least partially complementary to a portion of one or more variants of said target sequence; a 3′-terminal nucleotide which is complementary to only one variant of said target sequence and at least one nucleotide with a base covalently modified at the exocyclic amino group with a sequence selected from a group consisting of SEQ ID NOs: 4, 5, 7, 8, 10, 11 and 18.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9506111B2 cover?
The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having a 3′-terminal nucleotide complementary to only one variant of the target sequence and having at least one nucleotide with a base covalently modified at the exocyclic amino group, where…
Who is the assignee on this patent?
Roche Molecular Systems Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6858. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).